Details for New Drug Application (NDA): 217565
The generic ingredient in EDARAVONE is edaravone. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the edaravone profile page.
Summary for 217565
| Tradename: | EDARAVONE |
| Applicant: | Pharmobedient |
| Ingredient: | edaravone |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 30MG/100ML (0.3MG/ML) | ||||
| Approval Date: | Oct 31, 2024 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 60MG/100ML (0.6MG/ML) | ||||
| Approval Date: | Oct 31, 2024 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
